In some clinical trials, the correlation between PCSK9 and immune response has been demonstrated in patients with atherosclerotic disease, coronary artery disease, systemic lupus erythematosus, and human immunodeficiency virus (HIV)-infected (28–31). Here, PCSK9 is linked to coronary artery disorder.